

# Immunization in the Americas

## 2021 Summary



**PAHO**

Pan American  
Health  
Organization

World Health  
Organization  
Americas

# preface

National immunization programs suffer negative impacts when disruptions resulting from natural disasters, social or economic crises occur. The COVID-19 pandemic has created significant impediments to the effective functioning of these programs, by causing interruptions in routine health services, thus, negatively impacting the Region's immunization coverage. This situation has further exacerbated the downward trend in routine vaccination coverage that the Region had already been experiencing as immunization programs faced various political, structural, and operational challenges. To minimize the pandemic's negative impact on vaccination coverage rates, PAHO developed a series of innovative strategies to support Member States (MS) in maintaining the functionality of their respective immunization services, within the context of the COVID-19 pandemic, so as to avoid further declines in coverage.

Additionally, the Region has been working to address difficulties in reaching populations in marginal peri-urban and urban areas, as well as in remote border, mountain, and jungle areas, where socioeconomically marginalized populations face access barriers to immunization and other health services. Additionally, access to health services, including vaccination, is very often non-existent or extremely challenging for diverse populations of migrants across the Region further increasing their vulnerabilities and accentuating these barriers. Meanwhile, the increased generation and widespread dissemination of misinformation and disinformation related to vaccines and immunization has fueled vaccine hesitancy in many populations both in the Region and globally. The combination of these and other setbacks has contributed to outbreaks of vaccine-preventable diseases (VPDs), like measles and diphtheria.

In this difficult environment, 51 countries and territories of the Region have begun the rollout of COVID-19 vaccination. More than 900 million vaccine doses have been administered in this Region as of the end of August 2021. Approximately 53% of those doses were applied in Latin America and the Caribbean (LAC) and about 26 of 100 people in LAC have complete vaccination schedules. However, the main challenge for most LAC countries continues to be access to COVID-19 vaccines in sufficient quantities and on a timely basis.

PAHO has been in close contact with countries to support the enhanced functioning of their national immunization programs. This support has included:


- Developing technical documents, tools, workshops, virtual seminars, and providing additional technical and financial support to COVID-19 vaccination efforts.
- Developing technical documents, tools, workshops, virtual seminars to address COVID-19 vaccine misinformation and hesitancy, as well as for other vaccines, and supporting these efforts.
- Supporting ongoing COVID-19 vaccine introduction needs.
- Adapting and disseminating recommendations from WHO's Strategic Advisory Group of Experts (SAGE) on immunization and PAHO's Technical Advisory Group (TAG) on Vaccine-Preventable Diseases.
- Technically and financially supporting countries in resuming follow-up vaccination campaigns that were suspended due to the pandemic.
- Technically and financially supporting the maintenance of routine immunization operations.
- Providing technical and financial support for immunization programs, as needs appear.

We are grateful to countries for their extraordinary efforts to sustain immunization as an essential public health service during the COVID-19 pandemic through the establishment of vaccination posts.

The decline in vaccination coverage together with the less-than-optimal epidemiological surveillance pose a real risk to protecting the historic milestones reached by the Region of the Americas in controlling VPDs. Additionally, the re-introduction or re-emergence of the VPDs that were previously eliminated, eradicated, or controlled in our Region is highly possible. Key actions are needed to improve the immunization situation in the Region, and in this regard, PAHO's Executive Committee in June 2021 approved the document entitled- *Re-invigorating Immunization as a Public Good for Universal Health*, for presentation at our 59th Directing Council in September 2021. This document suggests a pathway forward for the revitalization of immunization.

Maintaining immunization as an essential program is an urgent priority. The COVID-19 pandemic and the introduction of COVID-19 vaccines in all countries require an intense and continued focus on this specific emergency response. However, the prevailing situation also simultaneously demands that routine immunization is not left at the wayside but continues to be a critical and essential public health program that will find and vaccinate those populations that were missed earlier in the pandemic.

Beyond the rollout of the COVID-19 vaccination effort, the overall strengthening and re-invigoration of immunization programs for VPDs should be a cornerstone of the post-pandemic recovery process. Vaccination is the most cost-effective health intervention for preventing VPDs. Enhanced and sustained investment in and commitment to every component of the immunization program will allow the Region of the Americas to reap the full health benefits of immunization.



Carissa F. Etienne  
Director  
Pan American Health Organization

For this publication:

- Latin America is composed of Mexico, Central America, Latin Caribbean, Andean Area, Brazil, and Southern Cone.
- Latin America and the Caribbean is composed of Latin America and Non-Latin Caribbean.
- Because of their population size, Brazil and Mexico are shown separately.

The data published in the brochure "*Immunization in the Americas*" may have been updated by the countries, after publication. To see the most up-to-date data, please visit: <https://www.paho.org/en/topics/immunization/immunization-data-and-statistics>.

# demographic and socioeconomic data

	1	2	3	4			5	6		7	8	9		10
	total population (thousands)	population <1 year old (thousands)	population 1 year old (thousands)	infant mortality rate (1,000 lb) or number of deaths (N)			women of childbearing age (thousands)	gross national income (US\$ per capita)		Gini index	national health expenditure as a % of GDP		public	private
				rate	(N)	year		current value	ppp value		2019	2018		
	2020	2020	2020	rate	(N)	year	2020	2020	2020	2019	2018	2018		
<b>The Americas</b>	1,022,624	14,627.0	14,644.2	12.2	139,852		736,995	28,708	33,634	45.3	5.5	5.2		
<b>North America</b>	368,817	4,393.1	4,344.4	5.7	24,036		236,370	63,621	64,165	40.6	8.4	7.8		
Bermuda	72	0.8	0.8	1.9	1	2018	41	117,740 <sup>H</sup>	86,450 <sup>H</sup>	...	...	...		
Canada	37,742	401.5	399.7	4.5	1,700	2017	23,164	43,440	47,500	33.3 <sup>K</sup>	7.9	2.9		
United States of America	331,003	3,990.8	3,943.9	5.8	22,335	2017	213,165	65,910 <sup>H</sup>	66,060 <sup>H</sup>	41.4 <sup>J</sup>	8.5	8.4		
<b>Latin America and the Caribbean</b>	653,808	10,233.9	10,299.8	14.8	115,816		500,626	7,592	15,169	48.3	4.1	3.8		
<b>Latin America</b>	646,267	10,124.8	10,188.7	14.8	114,130		495,055	7,509	15,118	48.3	4.1	3.8		
Mexico	128,933	2,140.7	2,172.9	12.1 <sup>A</sup>	26,995	2017	101,683	8,480	18,170	45.4	2.7	2.7		
<b>Central America Isthmus</b>	50,737	1,029.5	1,023.6	17.0	12,063		42,153	4,915	9,955	46.1	3.5	3.2		
Belize	398	7.9	7.9	12.6	98	2018	335	3,970	5,880	...	3.9	1.6		
Costa Rica	5,094	67.5	68.9	8.4 <sup>B</sup>	573	2018	3,725	11,460	19,840	48.2	5.5	2.1		
El Salvador	6,486	116.7	115.8	9.2 <sup>D</sup>	1,029	2018	5,136	3,650	8,050	38.8	4.5	2.6		
Guatemala	17,916	419.4	416.5	20.0	7,626	2017	15,566	4,490	8,690	...	2.1	3.6		
Honduras	9,905	211.3	206.2	22.8 <sup>D</sup>	...	2016	8,495	2,200	5,050	48.2	2.8	4.0		
Nicaragua	6,625	129.4	130.7	12.2 <sup>B</sup>	1,674	2018	5,542	1,850	5,410	...	5.1	3.0		
Panama	4,315	77.3	77.8	14.0	1,063	2017	3,354	11,880	25,010	49.8	4.6	2.6		
<b>Latin Caribbean</b>	37,512	585.4	593.9	34.0	5,240		27,647	6,181	11,436	41.9	4.5	2.7		
Cuba	11,327	101.0	109.5	4.0	461	2018	6,952	...	...	...	9.9	1.2		
Dominican Republic	10,848	200.0	200.5	22.8	4,420	2018	8,628	7,260	17,060	41.9	2.5	3.1		
French Guiana	299	7.8	7.4	7.9	56 <sup>E</sup>	2013-15	245	...	...	...	...	...		
Guadeloupe	400	5.4	4.8	8.9	43 <sup>E</sup>	2013-15	233	...	...	...	...	...		
Haiti	11,403	254.5	253.5	59.0 <sup>C</sup>	...	2016-17	9,730	1,250	2,930	...	0.9	3.8		
Martinique	375	4.3	3.9	7.3	88	2014-16	203	...	...	...	...	...		
Puerto Rico	2,861	12.4	14.2	7.1 <sup>B</sup>	172	2017	1,655	21,740	24,010	...	...	...		
<b>Andean Area</b>	141,607	2,354.0	2,351.0	15.8	19,537		109,842	5,542	12,268	46.6	4.0	2.2		
Bolivia (Plurinational State of)	11,673	236.9	237.1	24.0 <sup>A</sup>	...	2011-16	9,579	3,200	8,250	41.6	4.5	1.7		
Colombia	50,883	750.4	745.1	16.8 <sup>F</sup>	7,220	2016	38,642	5,780	14,280	51.3	5.5	2.2		
Ecuador	17,643	335.9	335.2	9.7 <sup>D</sup>	3,252	2017	14,111	5,530	10,580	45.7	4.2	3.9		
Peru	32,972	620.7	585.6	15.0 <sup>C</sup>	...	2017	25,534	6,010	11,490	41.5	3.3	1.9		
Venezuela (Bolivarian Republic of)	28,436	410.1	448.1	15.2	9,065	2014	21,976	...	...	...	1.7	1.9		
<b>Brazil</b>	212,559	2,870.9	2,887.6	13.4 <sup>E</sup>	40,425	2,017	158,281	7,850	14,550	53.4	4.0	5.5		
<b>Southern Cone</b>	74,918	1,144.3	1,159.7	9.2	9,870		55,449	10,048	20,512	43.4	5.3	3.8		
Argentina	45,196	740.6	745.9	9.3	6,579	2017	33,750	8,930	20,210	42.9	5.9	3.7		
Chile	19,116	214.0	225.3	7.1	1,557	2017	13,441	13,470	23,980	44.4 <sup>K</sup>	4.6	4.5		
Paraguay	7,133	143.1	141.3	12.6 <sup>D</sup>	1,461	2017	5,878	5,140	12,590	45.7	2.9	3.7		
Uruguay	3,474	46.6	47.1	6.8	273	2018	2,380	15,830	21,630	39.7	6.7	2.5		
<b>Non-Latin Caribbean</b>	7,541	109.1	111.1	17.5	1,686		5,571	19,020	22,167	0.0	3.7	2.5		
Anguilla	18	0.2	0.3	20.7	3	2017	13	...	...	...	...	...		
Antigua and Barbuda	98	1.4	1.5	18.0	20	2017	71	14,250	18,610	...	2.9	2.3		
Aruba	107	1.4	1.3	2.5	3	2017	66	...	...	...	...	...		
Bahamas	393	6.0	5.6	16.0	70	2016	296	27,780	31,200	...	3.1	3.1		
Barbados	287	3.2	3.1	14.2	37	2016	181	14,460	13,010	...	2.9	3.5		
BES*	...	...	...	...	...	...	...	...	...	...	...	...		
British Virgin Islands	37	0.4	0.4	16.5	4	2017	26	...	...	...	...	...		
Cayman Islands	62	0.8	0.8	9.4	6	2017	39	68,200 <sup>H</sup>	58,100 <sup>H</sup>	...	...	...		
Curaçao	164	1.6	1.7	10.3	16	2017	99	20,370	26,670	...	...	...		
Dominica	74	1.1	1.1	13.8 <sup>B</sup>	10	2018	52	6,870	10,740	...	4.3	2.2		
Grenada	113	1.8	1.8	12.5	19	2018	84	8,740	14,370	...	1.7	2.6		
Guyana	787	14.3	14.6	18.9 <sup>D</sup>	290	2018	622	6,600	15,370	...	3.7	2.1		
Jamaica	2,961	44.4	45.6	20.9 <sup>D</sup>	756	2016	2,248	4,620	8,850	...	3.9	2.0		
Montserrat	5	0.1	0.1	0.0	0	2017	4	...	...	...	...	...		
Saint Kitts and Nevis	54	0.7	0.7	27.0	16	2018	38	17,400	24,190	...	2.5	2.8		
Saint Lucia	184	2.1	2.1	12.9	24	2017	133	8,790	12,200	...	2.1	2.3		
Saint Vincent and the Grenadines	111	1.4	1.5	16.6	29	2016	81	7,340	12,810	...	3.1	1.4		
Sint Maarten	44	0.6	0.6	14.6	6	2018	27	27,680 <sup>J</sup>	35,390 <sup>J</sup>	...	...	...		
Suriname	587	10.3	10.4	14.0 <sup>D</sup>	137	2017	458	5,510	15,000	...	5.3	2.6		
Trinidad and Tobago	1,399	16.7	17.2	11.4 <sup>BDF</sup>	190	2017	988	15,410	24,800	...	3.4	3.5		
Turks and Caicos Islands	56	0.8	0.8	11.0	5	2018	45	30,700 <sup>H</sup>	30,060 <sup>H</sup>	...	...	...		

\*Bonaire, Saint Eustatius, and Saba.

(A) study; (B) preliminary; (C) survey; (D) data have one or more of the following limitations: coverage of maternal deaths and live births, differences in the maternal death definition, different denominators used, the analysis of only confirmed maternal deaths, and coverage of infant and neonatal deaths; (E) estimate; (F) public sector only; (G) value 2015; (H) value 2019; (J) value 2018; (K) value 2017.

# reported immunization coverage

	11	12	13	14	15	16	17	18	19	20	21	22	
	percentage of coverage												
	<1 year of age										1 year of age		
	BCG	HepB birth	IPV1	polio3	DTP1-vc <sup>D</sup>	DTP3-vc <sup>D</sup>	DTP1-3 dropout rate	rotavirus	PCV3	DTP4	MMR1	MMR2 <sup>G</sup>	
	2020	2020	2020	2020	2020	2020	2020	2020	2020	2020	2020	2020	
<b>The Americas</b>	71	68	89	82	91	85	10.7	78	82	75	88	64	
<b>North America</b>	NA	69	96	92	97	93	...	76	82	80	91	83	
Bermuda	NA	NA	93	89	93	89	3.6	83	92	84	99	74	
Canada <sup>A</sup>	NA	...	...	92	...	...	...	84	84	78	90	83	
United States of America <sup>B</sup>	NA	69	96	92	97	93	...	75	82	81	91	0	
<b>Latin America and the Caribbean</b>	71	67	86	78	89	82	10.7	79	82	73	86	64	
<b>Latin America</b>	71	67	86	77	89	82	10.8	79	82	73	86	64	
Mexico	33	60	92	86	92	86	6.7	82	87	78	104	83	
<b>Central America</b>	88	77	86	83	91	84	7	87	86	82	88	79	
Isthmus	76	67	79	79	79	79	0.3	...	...	84	82	87	
Belize	89	89	100	97	100	97	3.3	97	94	93	95	81	
Costa Rica	79	75	76	64	79	72	9.2	75	78	66	71	56	
El Salvador	86	NA	81	83	92	83	9.6	85	86	80	88	79	
Guatemala	83	71	85	80	85	80	5.1	83	80	79	82	79	
Honduras	100 <sup>C</sup>	NA	100 <sup>C</sup>	100 <sup>C</sup>	100 <sup>C</sup>	100 <sup>C</sup>	-3.0	100 <sup>C</sup>	100 <sup>C</sup>	100 <sup>C</sup>	100 <sup>C</sup>	100 <sup>C</sup>	
Nicaragua	100	86	97	74	97	74	23.8	86	74	78	80	74	
Panama													
<b>Latin Caribbean</b>	93	100	94	77	98	86	13.0	81	73	70	86	60	
Cuba	100	100	100	98	99	99	0.2	NA	NA	99	98	99	
Dominican Republic	99	...	94	80	95	82	13.6	77	69	72 <sup>E</sup>	82	55 <sup>E</sup>	
French Guiana	...	...	...	...	...	...	...	...	...	...	...	...	
Guadeloupe	...	...	...	...	...	...	...	...	...	...	...	...	
Haiti	86	...	92	66	100 <sup>C</sup>	83	17.7	83	76	55 <sup>E</sup>	83 <sup>F</sup>	45 <sup>E</sup>	
Martinique	...	...	...	...	...	...	...	...	...	...	...	...	
Puerto Rico	...	...	...	...	...	...	...	...	...	...	...	...	
<b>Andean Area</b>	85	73	85	72	85	73	14.2	80	79	63	81	60	
Bolivia (Plurinational State of)	82	...	79	68	79	68	13.7	74	68	54	74	46	
Colombia	89	88	92	88	92	88	4.9	87	89	82	90	88	
Ecuador	81	62	80	72	74	70	5.2	75	76	75	81	70	
Peru	87	75	92	61	93	72	22.3	76	74	59	77	52	
Venezuela (Bolivarian Republic of)	82	50	68	62	73	54	25.5	...	...	30	76	28	
<b>Brazil</b>	73	63	81	74	88	86	13.1	76	...	77	79	44	
<b>Southern Cone</b>	81	78	83	77	83	77	5.6	71	77	69	80	73	
Argentina	75	72	80	74	79	74	6.1	72	75	67	77	71	
Chile	100 <sup>C</sup>	100	98	93	98	93	3.1	...	89	81	91	83	
Paraguay	72	...	72	65	72	67	7.7	68	67	55	68	60	
Uruguay	100	NA	97	91	98	92	5.8	NA	94	94	95	91	
<b>Non-Latin Caribbean</b>	98	75	92	89	92	91	2.0	95	31	80	91	83	
Anguilla	86	100	72	82	71	86	-15.2	...	80	62	80	66	
Antigua and Barbuda	NA	NA	95	95	95	96	0.0	NA	...	90	89	78	
Aruba	...	...	...	...	...	...	...	...	...	...	...	...	
Bahamas	NA	...	97	83	97	83	14.3	95	83	83	87	83	
Barbados	NA	...	86	85	86	85	0.9	...	86	79	89	78	
BES*	...	...	...	...	...	...	...	...	...	...	...	...	
British Virgin Islands	NA	94	81	87	85	87	-2.9	...	...	80	99	97	
Cayman Islands	85	75	96	85	96	85	13.1	74	92	77	82	62	
Curaçao	...	...	...	...	...	...	...	...	...	...	...	...	
Dominica	98	99	100	97	100	97	3.8	...	...	90	92	90	
Grenada	NA	92	79	...	79	72	8.1	...	...	69	83	79	
Guyana	94	49	99	91	100 <sup>C</sup>	100	2.6	97	89	80	100 <sup>C</sup>	97	
Jamaica	100	...	95	95	94	96	-1.5	...	1	86	93	89	
Montserrat	...	...	...	...	...	...	...	...	...	...	...	...	
Saint Kitts and Nevis	98	97	99	99	100	99	-1.6	...	...	98	99	99	
Saint Lucia	89	86	90	88	90	86	4.6	...	...	74	89	71	
Saint Vincent and the Grenadines	100	96	100	100 <sup>C</sup>	100	100 <sup>C</sup>	-5.5	...	...	99	100 <sup>C</sup>	100 <sup>C</sup>	
Sint Maarten	...	...	...	...	...	...	...	...	...	...	...	...	
Suriname	NA	98	72	65	72	65	9.9	...	...	48	66	35	
Trinidad and Tobago	...	...	...	...	...	...	...	...	...	...	...	...	
Turks and Caicos Islands	100	...	84	84	84	84	0.0	...	...	88	95	83	

\*Bonaire, Saint Eustatius, and Saba.

(A) <2 years of age; (B) children aged 19-35 months; (C) reported coverage >100%; (D) diphtheria-tetanus-pertussis containing vaccine; (E) no data but in schedule; (F) coverage report for measles-rubella vaccine in children <1 year of age; (G) target age groups vary by country.

# morbidity data

	23	24	25	26	27	28	29	30	31	32	33	34
	number of confirmed cases											
	VDPV <sup>A</sup>	measles	rubella	covid-19 <sup>E</sup>	non-neonatal tetanus	neonatal tetanus	yellow fever	pertussis	diphtheria	mumps	Hib meningitis	meningitis pneumo-coccal
	2020	2020	2020	2020	2020	2020	2020	2020	2020	2020	2020	2020
<b>The Americas</b>	0	8,734	2	36,516,014	357	12	27	7,321	81	19,044	103	262
<b>North America</b>	0	14	2	20,743,103	18	0	1	6,365	3	708	20	0
Bermuda	0	0	0	604	0	0	0	8	0	1	0	0
Canada	0	1	1	588,277	3	...	1	955	1	86	9	0
United States of America <sup>B</sup>	0	13 <sup>C</sup>	1 <sup>C</sup>	20,154,222	15	0	0	5,402	2	621	11 <sup>F</sup>	...
<b>Latin America and the Caribbean</b>	0	8,720	0	15,772,911	339	12	26	956	78	18,336	83	262
<b>Latin America</b>	0	8,720	0	15,718,245	338	12	26	952	78	18,336	83	250
Mexico	0	196	0	1,437,185	14	1	0	251	...	3,522	0	8
<b>Central America Isthmus</b>	0	0	0	743,492	8	2	0	35	0	1,859	2	21
Belize	0	0	0	10,807	0	0	0	0	0	4	0	0
Costa Rica	0	0	0	170,591	0	0	0	10	0	195	0	1
El Salvador	0	0	0	46,242	0	0	0	0	0	256	0	0
Guatemala	0	0	0	138,316	0	0	0	13	0	398	0	0
Honduras	0	0	0	122,974	8	2	0	11	0	547	0	1
Nicaragua	0	0	0	4,829	0	0	0	0	0	11	0	0
Panama	0	0	0	249,733	0	0	0	1	0	448	2	19
<b>Latin Caribbean</b>	0	0	0	301,183	86	4	0	8	69	736	5	32
Cuba	0	0	0	12,225	0	0	0	0	0	0	5	32
Dominican Republic	0	0	0	172,965	24	0	0	8	3	736	0	0
French Guiana	...	...	...	13,273	...	...	...	...	...	...	...	...
Guadeloupe	...	...	...	8,620	...	...	...	...	...	...	...	...
Haiti	0	0	0	10,077	62	4	0	0	66	0	0	0
Martinique	...	...	...	6,091	...	...	...	...	...	...	...	...
Puerto Rico	0	...	...	77,932	...	...	...	...	...	...	...	...
<b>Andean Area</b>	0	3	0	3,162,209	41	5	8	136	7	6,020	25	69
Bolivia (Plurinational State of)	0	2	0	162,055	0	0	0	12	0	0	0	0
Colombia	0	1	0	1,654,880	19	2	0	68	0	5,125	20	67
Ecuador	0	0	0	214,513	3	0	0	8	0	326	0	0
Peru	0	0	0	1,017,199	16	3	8	47	4	486	0	0
Venezuela (Bolivarian Republic of)	0	0	0	113,562	3	0	0	1	3	83	5	2
<b>Brazil</b>	0	8,448 <sup>D</sup>	0	7,700,578	173	0	18	229	1	0	30	0
<b>Southern Cone</b>	0	73	0	2,373,598	16	0	0	293	1	6,199	21	120
Argentina	0	69	0	1,629,594	4	0	0	162	0	3,776	17	57
Chile	0	2	0	615,902	8	0	0	62	1	2,110	1	43
Paraguay	0	0	0	108,349	4	0	0	15	0	128	2	14
Uruguay	0	2	0	19,753	0	0	0	54	0	185	1	6
<b>Non-Latin Caribbean</b>	0	0	0	54,666	1	0	0	4	0	0	0	12
Anguilla	0	0	0	15	0	0	0	0	0	0	0	0
Antigua and Barbuda	0	0	0	159	0	0	0	0	0	0	0	9
Aruba	0	0 <sup>C</sup>	0 <sup>C</sup>	5,442	...	...	...	...	...	...	...	...
Bahamas	0	0	0	8,188	0	0	0	0	0	0	0	0
Barbados	0	0	0	395	0	0	0	0	0	0	0	0
BES*	...	...	...	...	...	...	...	...	...	...	...	...
British Virgin Islands	0	0	0	93	0	0	0	0	0	0	0	0
Cayman Islands	0	0	0	338	0	0	0	0	0	0	0	0
Curaçao	0	0 <sup>C</sup>	0 <sup>C</sup>	4,230	...	...	...	...	...	...	...	...
Dominica	0	0	0	96	0	0	0	0	0	0	0	0
Grenada	0	0	0	130	0	0	0	0	0	0	0	0
Guyana	0	0	0	6,351	0	0	0	0	0	0	0	0
Jamaica	0	0	0	12,931	0	0	0	0	0	0	0	0
Montserrat	0	0 <sup>C</sup>	0 <sup>C</sup>	13	...	...	...	...	...	...	...	...
Saint Kitts and Nevis	0	0	0	33	0	0	0	0	0	0	0	0
Saint Lucia	0	0	0	353	0	0	0	0	0	0	0	0
Saint Vincent and the Grenadines	0	0	0	122	0	0	0	0	0	0	0	0
Sint Maarten	0	0 <sup>C</sup>	0 <sup>C</sup>	1,434	...	...	...	...	...	...	...	...
Suriname	0	0	0	6,277	1	0	0	4	0	0	0	3
Trinidad and Tobago	0	0 <sup>C</sup>	0 <sup>C</sup>	7,158	...	...	...	...	...	...	...	...
Turks and Caicos Islands	0	0	0	908	0	0	0	0	0	0	0	0

\*Bonaire, Saint Eustatius, and Saba.

(A) no countries reported wildpolio virus in the Americas; (B) CDC Wonder, National Notifiable Diseases Surveillance System (NNDSS), provisional data as of epidemiological week 32 (August 2021); (C) Measles/Rubella Weekly Surveillance Bulletin, 2020; (D) re-establishment of endemic transmission; (E) WHO Covid-19 Detailed Surveillance Data Dashboard; (F) invasive disease, age <5 years.

# program management and financing

	35	36	37	38	39	40	41	42	43	44
	years covered by multi-year plan for immunization	number of NITAG <sup>a</sup> meetings	total number of districts/ municipalities	% of municipalities w/ coverage level ≥95% DTP3	% of children in municipalities w/ coverage level ≥95% DTP3	plan for immunization injection safety	number of "serious" ESAVIs reported	spending on routine immunization financed using gov't funds (%)	spending on vaccine purchases financed using gov't funds (%)	year vaccine law formed
	2020	2020	2020	2020	2020	2020	2020	2020	2020	2020
<b>The Americas</b>		197	15,047	32	28		3,626			
<b>North America</b>		27	162	...	...		2,867			
Bermuda	no	0	1	...	...	no	0	...	...	1974
Canada	...	17	111	...	...	...	209	...	...	...
United States of America	...	10	50 <sup>b</sup>	...	...	yes	2,658	...	...	...
<b>Latin America and the Caribbean</b>		170	14,885	32	28		759			
<b>Latin America</b>		139	14,750	32	28		755			
Mexico	2020–2024	...	2,469	33	32	yes	111	100	100	2017
<b>Central America Isthmus</b>		63	1,221	35	26		86			
Belize	2020–2022	8	6	0	0	yes	1	100	100	no
Costa Rica	no	24	81	63	56	yes	0	...	...	2001
El Salvador	yes	6	262	19	11	yes	53	98	98	2014
Guatemala	2020–2024	12	340	31	20	no	0	100	100	no
Honduras	2020–2021	3	298	29	10	yes	22	97	95	2014
Nicaragua	2020–2021	2	153	84	83	yes	10	89	89	2002
Panama	2020–2024	8	81	13	2	yes	0	100	100	2007
<b>Latin Caribbean</b>		12	465	57	37		4			
Cuba	2020–2020	9	168	100	100	yes	4	99	98	1983
Dominican Republic	2019–2022	0	157	33	23	no	0	100	100	no
French Guiana	...	...	...	...	...	...	...	...	...	...
Guadeloupe	...	...	...	...	...	...	...	...	...	...
Haiti	2016–2020	3	140	32	22	yes	0	79	...	no
Martinique	...	...	...	...	...	...	...	...	...	...
Puerto Rico	...	...	...	...	...	...	...	...	...	...
<b>Andean Area</b>		33	3,892	27	14		399			
Bolivia (Plurinational State of)	2016–2020	15	340	4	3	yes	0	92	100	2020
Colombia	2020–2021	2	1,122	42	31	yes	338	...	...	2001
Ecuador	no	4	221	10	3	yes	14	100	100	2006
Peru	no	12	1,874	38	12	no	46	...	...	2003
Venezuela (Bolivarian Republic of)	no	0	335	10	5	yes	1	...	25	1996
<b>Brazil</b>	...	...	5,570	...	...	...	0	...	...	...
<b>Southern Cone</b>		31	1,133	33	13		155			
Argentina	no	5	512	27	10	yes	41	...	...	2019
Chile	2020–2021	12	346	62	33	yes	70	...	...	2010
Paraguay	no	10	255	8	3	yes	24	99	100	2012
Uruguay	2015–2020	4	20	20	6	yes	20	100	100	1982
<b>Non-Latin Caribbean</b>		31	135	38	57		4			
Anguilla	no	0	3	33	33	no	0	100	100	2018
Antigua and Barbuda	–2222	2	8	...	26	...	0	...	...	...
Aruba	...	...	...	...	...	...	...	...	...	...
Bahamas	...	2	16	50	7	...	0	...	...	...
Barbados	no	2	10	10	21	no	0	100	100	no
BES*	...	...	...	...	...	...	...	...	...	...
British Virgin Islands	2019–2023	0	4	...	...	yes	0	100	100	no
Cayman Islands	no	2	6	17	3	no	0	...	...	no
Curaçao	...	...	...	...	...	...	...	...	...	...
Dominica	no	2	7	71	73	yes	2	93	100	no
Grenada	2016–2025	2	7	...	...	yes	0	100	100	1980
Guyana	2015–2020	2	13	...	...	yes	0	...	...	no
Jamaica	no	2	13	69	82	no	2	100	100	2013
Montserrat	...	...	...	...	...	...	...	...	...	...
Saint Kitts and Nevis	no	6	17	...	...	yes	0	...	...	...
Saint Lucia	no	5	8	38	53	yes	...	...	...	no
Saint Vincent and the Grenadines	no	2	9	78	79	no	0	100	100	no
Sint Maarten	...	...	...	...	...	...	...	...	...	...
Suriname	2020–2025	2	10	...	...	yes	0	100	100	yes
Trinidad and Tobago	...	...	...	...	...	...	...	...	...	...
Turks and Caicos Islands	no	...	4	...	...	no	...	99	100	no

\*Bonaire, Saint Eustatius, and Saba.

(A) NITAG: national immunization technical advisory group; (B) reports number of states.

# surveillance indicators

## Acute Flaccid Paralysis (AFP), 2020\*

Country	Number of AFP cases	AFP rate (x 100,000 <15 years old)	% of cases investigated within <48 hours	% of cases with 1 adequate sample	Number of compatible cases
Argentina	86	0.78	34	74	0
Bolivia	16	0.45	100	75	0
Brazil	248	0.56	98	67	0
Canada	7	0.12	0	29	0
CARPHA	4	0.22	50	25	0
Chile	41	1.11	71	66	0
Colombia	110	0.85	76	79	0
Costa Rica	14	1.32	93	93	0
Cuba	21	1.16	81	95	0
Dominican Republic	11	0.37	9	55	0
Ecuador	20	0.41	80	70	0
El Salvador	17	0.99	47	94	0
Guatemala	39	0.65	79	72	0
Haiti	8	0.22	50	38	0
Honduras	50	1.65	82	90	0
Mexico	474	1.42	99	82	0
Nicaragua	18	0.92	89	78	0
Panama	11	0.96	45	100	0
Paraguay	19	0.92	89	58	0
Peru	45	0.55	64	69	0
Uruguay	1	0.14	0	100	0
Venezuela	74	0.95	96	53	2
TOTAL/AVERAGE	1,334	0.82	85	75	2

Source: Integrated Surveillance Information System, Polio Eradication Surveillance System, and country reports to FPL-IM/PAHO.

\*Data as of epidemiological week 31 (August 2021).

## Measles/Rubella/CRS Surveillance Indicators, 2020\*

Country	Number of suspected MR cases	% of cases with adequate investigation	% of cases with adequate samples	% of samples received in lab in ≤5 days	% of laboratory samples with results in ≤4 days	Rate of suspected MR cases per 100,000 population	Rate of suspected CRS cases per 10,000 live births
Argentina	1825	19	90	83	56	4.0	0.7
Bolivia	137	94	94	82	90	1.2	0.0
Brazil	17406	...	66	91	69	8.2	0.1
CARPHA	55	60	96	22	76	0.7	1.0
Chile	49	8	96	87	94	0.3	0.0
Colombia	737	93	93	96	100	1.5	7.9
Costa Rica	104	96	99	96	97	2.0	19.0
Cuba	1540	100	100	100	100	13.6	0.0
Dominican Republic	47	40	77	78	57	0.4	0.0
Ecuador	228	90	68	35	65	1.3	0.0
El Salvador	191	87	100	98	93	2.9	0.0
Guatemala	71	99	99	55	85	0.4	0.0
Haiti	142	92	95	58	58	1.2	1.9
Honduras	118	97	100	85	99	1.2	0.5
Mexico	2504	95	99	94	90	1.9	0.0
Nicaragua	125	95	97	94	97	1.9	1.8
Panama	30	100	97	67	90	0.7	0.0
Paraguay	573	77	92	86	94	8.0	0.4
Peru	76	92	82	55	51	0.2	0.0
Uruguay	11	64	27	38	38	0.3	0.0
Venezuela	796	95	96	31	11	1.6	0.0
TOTAL/AVERAGE	26,765	89	80	75	66	4.1	1.0

Source: Integrated Surveillance Information System, Polio Eradication Surveillance System, and country reports to FPL-IM/PAHO.

\*Data as of epidemiological week 31 (August 2021).



# technical notes and data sources

## Main Data Sources

For detailed information on demographic data and socioeconomic indicators, please visit: [www.paho.org/datastatistics](http://www.paho.org/datastatistics).

**Demographic data (Columns 1-3, 5):** World Population Prospects 2019, Online Edition. Accessed September 2019 (<http://esa.un.org/wpp/>). For countries not included in the UN World Population Prospects: U.S. Bureau of the Census. International Data Base. Accessed September 2019 (<https://www.census.gov/data-tools/demo/idb/informationGateway.php>). Women of childbearing age includes women aged 15 to 49 years.

**Infant mortality rate (1,000 lb) or number of deaths (N) (Column 4):** PAHO/WHO. Data provided by Ministries of Health or National Health Agencies of countries. Washington, D.C., 2019. As of August 2019.

**Socioeconomic indicators (Columns 6-10):** The World Bank (2021). World Development Indicators 2021. Washington, D.C. July 2021 Update. Accessed July 30, 2021 (<http://databank.worldbank.org/data/home.aspx>). Estimates of the national health expenditure: PAHO/WHO. Data compiled by the Department of Health Systems and Services from the Global Health Expenditure Database. Washington, D.C., 2021. As of July 2021 (<http://www.who.int/health-accounts/ghed/en/>).

**Immunization coverage, immunization program management, and financing information (Columns 11-22, 35-44):** Annual country reports to Comprehensive Family Immunization Unit (IM)/PAHO via PAHO-WHO/UNICEF electronic Joint Reporting Form (eJRF); 2021.

**Morbidity (Columns 23-34):** Annual country reports to IM/PAHO via JRF, vaccine-preventable disease specific surveillance reports for measles/rubella and polio to IM/PAHO; 2020-2021.

**Surveillance indicators:** Vaccine-preventable disease specific surveillance reports for measles/rubella and acute flaccid paralysis/polio to IM/PAHO; 2020-2021.

## Symbols and Abbreviations

(pop) population; (lb) live births; (NA) not applicable; (...) no data; (ppp) purchase power parity; (int'l) international; (GDP) gross domestic product; (BCG) bacille Calmette-Guérin (anti-tuberculosis vaccine); (HepB) hepatitis B; (IPV1) first dose of inactivated polio vaccine; (Polio3) third dose of polio vaccine (oral polio vaccine or inactivated polio vaccine); (DTP1) first dose of diphtheria-tetanus-pertussis vaccine (as DTP or DTP containing vaccine); (DTP3) third dose of diphtheria-tetanus-pertussis vaccine (as DTP containing vaccine); (Rotavirus) last dose of rotavirus vaccine; (PCV3) third dose of pneumococcal conjugate vaccine; (DTP4) first booster dose after the primary series consisting of three doses of diphtheria-tetanus-pertussis vaccine (as DTP or DTP containing vaccine); (MMR1) first dose of measles, mumps, rubella vaccine; (MMR2) second dose of measles, mumps, rubella vaccine (when offered in the routine program); (VDPV) vaccine-derived poliovirus; (CRS) congenital rubella syndrome; (Hib)

*Haemophilus influenzae* type b; (NITAG) national immunization technical advisory group; (ESAVI) event supposedly attributable to vaccination or immunization; (gov't) government; (CARPHA) Caribbean Public Health Agencies; (HPV) human papillomavirus; (m) months; (y) years.

## Technical Notes

**Immunization coverage:** Proportion of children aged <1 year vaccinated with one dose of BCG vaccine, hepatitis B vaccine given at birth, first dose of inactivated polio vaccine, the third dose of polio vaccine (oral polio vaccine or inactivated polio vaccine), the first dose of DTP, the third dose of DTP, and the last dose of rotavirus vaccine (2nd or 3rd dose depending on the vaccine used), respectively. Proportion of children vaccinated with the 3rd dose of PCV in children <1 or ≥1 year according to vaccine schedule of the country. Proportion of children aged 1 year vaccinated with the first booster of DTP vaccine, and one dose of MMR vaccine. Proportion of children vaccinated with a second dose of MMR vaccine, as targeted in countries offering a second MMR dose in the routine program. Coverage rates are expressed as a percentage of the corresponding mid-year population, as reported by the country. Reported coverage rates ≥100% are presented as 100% with a footnote. Regional and subregional aggregated data express average values weighted by population aged <1 year and 1 year, when country data are available.

**Dropout rate DTP1-DTP3:** Number of DTP1 doses administered minus the number of DTP3 doses administered (among children aged <1 year) divided by the number of DTP1 doses, expressed as a percentage.

**Morbidity:** Number of confirmed cases of VDPV, measles, rubella, COVID-19, non-neonatal tetanus, neonatal tetanus, yellow fever, pertussis, diphtheria, Hib meningitis, mumps, and meningitis pneumococcal. Subregional aggregated data are the sum of the totals. These are not rates; hence, inter-country comparisons may not be appropriate.

## Immunization program management and financing:

- Multi-year plan for immunization: Existence of an immunization strategic plan for more than one year.
- Number of NITAG meetings: Number of times the NITAG met in 2020. NITAGs provide recommendations on immunization practices, including advice on vaccines to be included in the national immunization schedule.
- Number of municipalities and number of children <1 year of age living in these municipalities reaching coverage ≥95% for DTP3: Proportion of municipalities and proportion of children <1 year of age living in these municipalities reporting coverage levels equal to or greater than 95% for DTP3, respectively, expressed as a percentage. Municipalities are defined as the third administrative level (country level being first), unless otherwise stated.
- Plan for immunization injection safety: The existence of a plan to ensure the safety of injections, including training, supervision, and the proper

## Selected Information Products from the Comprehensive Family Immunization Unit



Please visit the Comprehensive Family Immunization page at [www.paho.org/immunization](http://www.paho.org/immunization)

© Pan American Health Organization, 2021. Some rights reserved. This work is available under license [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/).



use of safety boxes. This plan may be part of the annual immunization plan of action.

- Number of ESAVIs reported as “serious”: An ESAVI will be considered serious if it results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. Other situations, such as other important medical events that may jeopardize the patient or may require intervention to prevent one of the outcomes above, should also be considered serious after applying medical and scientific judgment.

- Spending on routine immunization financed using government funds: Percentage of all recurrent immunization-specific spending that was financed using government funds (for all recurrent inputs, including vaccines, injection supplies, salaries and per-diems of health staff working full-time on immunization, transport, vehicles and cold chain maintenance, training, social mobilization, monitoring, and surveillance). This excludes any external financing from donors, but may include loans.

- Spending on vaccine purchases financed using government funds: Percentage of all vaccine spending that was financed using government funds. This excludes any external financing from donors, but may include loans.

- Vaccine law: When country formed its vaccine law.

**Surveillance indicators:** For measles/rubella definitions refer to PAHO. Measles Elimination: Field Guide (Scientific and Technical Publication No. 605). Washington, DC: PAHO; 2005. For acute flaccid paralysis definitions refer to PAHO. Poliomyelitis Eradication: Field Guide (Scientific and Technical Publication No. 607). Washington D.C.: PAHO; 2005. Available at [http://www.paho.org/english/ad/fch/im/FieldGuide\\_Index.htm](http://www.paho.org/english/ad/fch/im/FieldGuide_Index.htm).

*This brochure is published in collaboration with the Health Analysis, Metrics and Evidence Unit, Department of Evidence and Intelligence for Action in Health (EIH/HA), Pan American Health Organization.*

## Seasonal Influenza Vaccine Use in the Americas, 2020


Country	Healthy Children		Elderly Adults		Other Risk Groups		
	Schedule	Coverage <sup>A</sup> (%)	Schedule	Coverage (%)	Health Workers (%)	Pregnant Women (%)	Chronic Diseases <sup>C</sup>
Anguilla	NA	NA	yes	...	yes	NA	yes
Antigua and Barbuda	NA	NA	≥65y	...	yes	NA	NA
Argentina	6m-24m	69	≥65y	71	100 <sup>B</sup>	77	68
Aruba	<2y	...	>60y	...	yes	yes	yes
Bahamas	≥6m	...	≥15y	...	yes	yes	yes
Barbados	NA	NA	NA	NA	yes	NA	NA
Belize	6m-35m	54	≥65y	6	12	yes	NA
Bermuda	6m-18y	13	>65y	12	yes	11	yes
BES*	...	...	...	...	...	...	...
Bolivia	6m-23m	61	≥60y	59	64	83	55
Brazil	6m-59m	67	≥60y	96	100 <sup>B</sup>	77	NA
British Virgin Islands	NA	NA	>10y	...	5	NA	44
Canada	≥6m	...	≥65y	70	yes	45	yes
Cayman Islands	≥6m	...	≥60y	...	yes	yes	yes
Chile	6m-59m	78	≥65y	85	100 <sup>B</sup>	75	100 <sup>B</sup>
Colombia	<1y	74	≥60y	89	yes	86	yes
Costa Rica	6m-<6y	...	≥60y	...	yes	yes	yes
Cuba	<2y	56	≥75y	100	93	75	87
Curaçao	NA	NA	NA	NA	NA	NA	NA
Dominica	6m-35m	...	≥65y	...	yes	yes	yes
Dominican Republic	6m-24m	7	≥65y	8	31	9	58
Ecuador	6m-59m	88	>65y	76	94	75	100 <sup>B</sup>
El Salvador	6m-59m	39	≥60y	37	100 <sup>B</sup>	49	yes
Grenada	6m-59m	...	>65y	...	yes	yes	yes
Guatemala	6m-35m	10	≥65y	0	47	16	yes
Guyana	NA	NA	NA	NA	NA	NA	NA
Haiti	NA	NA	NA	NA	NA	NA	NA
Honduras	6m-23m	53	≥60y	56	82	84	100 <sup>B</sup>
Jamaica	6m-17y	1	≥65y	20	18	7	yes
Mexico	6m-59m	87	≥60y	94	100 <sup>B</sup>	78	100 <sup>B</sup>
Montserrat	NA	NA	yes	...	yes	NA	NA
Nicaragua	NA	NA	NA	NA	100	yes	100
Panama	6m-59m	61	≥60y	99	89	73	yes
Paraguay	6m-36m	23	≥60y	47	yes	16	yes
Peru	<5y	81	>60y	69	yes	44	yes
Saint Kitts and Nevis	NA	NA	≥18y	...	yes	yes	NA
Saint Lucia	NA	NA	≥60y	...	yes	yes	yes
Saint Vincent and the Grenadines	NA	NA	NA	NA	NA	NA	NA
Sint Maarten	NA	NA	NA	NA	NA	NA	NA
Suriname	NA	NA	≥55y	...	yes	yes	yes
Trinidad and Tobago	6m-5y	...	>65y	...	yes	yes	yes
Turks and Caicos	≥6m	...	≥50y	...	yes	yes	yes
United States of America**	≥6m-17y	64	≥65y	70	81	66	yes
Uruguay	6m-59m	7	≥65y	52	100 <sup>B</sup>	55	yes
Venezuela	NA	NA	≥60y	11	51	NA	73

\*Bonaire, Saint Eustatius, and Saba; \*\*USA data during 2019-2020 influenza season; m-month(s); y-year(s).

(A) pediatric coverage formula: ((2nd dose+single dose)/denominator)\*100; (B) reported coverage >100%; (C) countries including adults with chronic diseases in their policy; yes - influenza vaccination recommended.

Source: Country reports through the PAHO-WHO/UNICEF electronic Joint Reporting Form (eJRF), 2021.

# Regional Immunization Action Plan Situation in the Americas, 2016-2020



## Number of Second HPV Vaccine Doses Administered Latin America and the Caribbean, 2020

Country	Type of Population	Number of Second HPV Vaccine Doses by Age						Unknown
		9 years	10 years	11 years	12 years	13 years	>14 years	
Anguilla	...	...	...	...	...	...	...	...
Antigua and Barbuda	...	...	...	...	...	...	...	...
Argentina	female and male	...	...	307,020	...	...	...	48,871
Aruba	...	...	...	...	...	...	...	...
Bahamas	female	19	...	...	...	...	666	...
Barbados	female and male	...	...	243	...	21	35	...
Belize	female and male	333	409	100	57	17	18	...
Bermuda	...	...	...	...	...	...	...	...
BES*	...	...	...	...	...	...	...	...
Bolivia	female	...	27,860	1,796	940	816	...	...
Brazil	female and male	332,342	334,886	452,777	390,919	204,993	247,362	...
British Virgin Islands	female	...	...	33	...	...	2	...
Canada	...	...	...	...	...	...	...	...
Cayman Islands	...	...	...	...	...	...	...	...
Chile	female and male	1,409	177,535	1,163	366	2,171	...	...
Colombia	female	34,182	34,380	20,930	16,884	14,465	37,758	...
Costa Rica	...	...	...	...	...	...	...	...
Cuba	...	...	...	...	...	...	...	...
Curaçao	...	...	...	...	...	...	...	...
Dominica	female and male	9	14	341	274	68	23	...
Dominican Republic	female	2,145	1501	983	596	668	1,148	...
Ecuador	female	56,365	...	...	...	...	...	...
El Salvador	...	...	...	...	...	...	...	...
Grenada	...	...	...	...	...	...	...	...
Guatemala	...	...	...	...	...	...	...	...
Guyana	...	...	...	...	...	...	...	...
Haiti	...	...	...	...	...	...	...	...
Honduras	female	...	...	46,849	5,944	...	...	...
Jamaica	female	...	...	8	168	428	167	...
Mexico	...	...	...	...	...	...	...	...
Montserrat	...	...	...	...	...	...	...	...
Nicaragua	...	...	...	...	...	...	...	...
Panama	female and male	...	70,760	...	...	...	...	...
Paraguay	...	...	...	...	...	...	...	...
Peru	...	...	...	...	...	...	...	...
Saint Kitts and Nevis	...	...	...	...	...	...	...	...
Saint Lucia	female and male	...	181	934	336	68	12	...
Saint Vincent and the Grenadines	female	...	...	...	...	103	...	...
Sint Maarten	...	...	...	...	...	...	...	...
Suriname	female	...	...	...	...	...	...	207
Trinidad and Tobago	...	...	...	...	...	...	...	...
Turks and Caicos Islands	...	...	...	...	...	...	...	...
United States of America	...	...	...	...	...	...	...	...
Uruguay	female and male	...	...	1,233	9,984	14,843	21,514	...
Venezuela	...	...	...	...	...	...	...	...

\*Bonaire, Saint Eustatius, and Saba.

Source: Country reports through the PAHO-WHO/UNICEF electronic Joint Reporting Form (eJRF), 2021.

# COVID-19 Complete Schedule Vaccination Coverage per 100 People in the Americas, 2020

<b>Countries/territories</b>	<b>Completed schedule</b>	<b>2nd doses administered</b>
51/51	335,395,341	307,938,236
<b>Total doses administered</b>	<b>1st doses administered</b>	<b>Single doses administered</b>
825,738,329	486,283,483	28,045,916



Source: [https://ais.paho.org/imm/IM\\_DosisAdmin-Vacunacion.asp](https://ais.paho.org/imm/IM_DosisAdmin-Vacunacion.asp)  
 Data accessed as of 26 August 2021.

# Vaccine Manufacturers and Brand Administered Region of the Americas, 2020-2021\*

AstraZeneca - Vaxsevia  
35 countries



Pfizer-BioNTech - Cominarty  
34 countries



SII - Covishield  
22 countries



Moderna - mRNA-1273  
16 countries



Beijing CNBG - BBIBP-CorV  
12 countries



Janssen - Ad26.COV.2.5  
12 countries



Gamaleya - Sputnik V  
11 countries



Sinovac - CoronaVac  
9 countries



CanSino - Ad5-nCOV  
3 countries



Bharat - Covaxin  
1 country



BioCubaFarma - Abdala, Soberana 02,  
Soberana Plus  
1 country



Julphar - Hayat-Vax  
1 country

